Genomics in cardiac metabolism

Cardiovascular Research

Volumn 79, Issue 2, 2008, Pages 218-227

  Samuel, Jane Lise ^a,b   Schaub, Marcus C ^c   Zaugg, Michael ^d   Mamas, Mamas ^e   Dunn, Warwick B ^f   Swynghedauw, Bernard ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiac metabolism; Genome wide analysis; Metabolomics; Transcriptomics

Indexed keywords

BIOLOGICAL MARKER;

GENE EXPRESSION REGULATION; GENE STRUCTURE; GENETIC ASSOCIATION; GENOME ANALYSIS; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

ANIMALS; GENOMICS; HEART DISEASES; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 46749137917     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn061     Document Type: Review

References (74)

1. Gibson G, Muse SV. A Primer of Genome Science. 2nd ed. Sunderland, MA: Sinauer Associate Publishers; 2005.
2. Wright A, Hastie N. Genes and Common Diseases. Cambridge, UK: Cambridge University Press; 2007. 3. Swynghedauw B. Susceptibility-conferring polymorphic genotypes in cardiovascular multifactorial syndromes. Eur Heart J 2002;23:271-273.
3. Kruglyak L. Power tools for human genetics. Nat Genet 2005
4. Freimer NB, Sabatti C. Human genetics: variants in common diseases. Nature 2007;445:828-830.
5. Cambien F, Tiret L. Genetics of cardiovascular diseases: from single mutations to the whole genome. Circulation 2007;116:1714-1724.
6. International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-1320.
7. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP et al. The diploid genome sequence of an individual human. PLoS Biol 2007;5:e254.
8. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007;447:661-678.
9. Cupples LA, Arruda HT, Benjamin EJ, D'Agostino RB Sr, Demissie S, DeStefano AL et al. The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet 2007;8(Suppl. 1):S1.
10. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007;357:443-453.
11. Hunter DJ, Kraft P. Drinking from the fire hose-statistical issues in genome-wide association studies. N Engl J Med 2007;357:436-439.
12. King JY, Ferrara R, Tabibiazar R, Spin JM, Chen MM, Kuchinsky A et al. Pathway analysis of coronary atherosclerosis. Physiol Genom 2005;23:103-118.
13. Steenman M, Lamirault G, Le Meur N, Le Cunff M, Escande D, Leger JJ. Distinct molecular portraits of human failing hearts identified by dedicated cDNA microarrays. Eur J Heart Fail 2005;7:157-165.
14. Leger J, Swynghedauw B. From molecular to modular cardiology. How to interpret the millions of data that came out from large scale analysis of gene expression? Arch Mal Coeur Vaiss 2006;99:231-236.
15. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E et al. Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genom 2005;21:299-307.
16. Nanni L, Romualdi C, Maseri A, Lanfranchi G. Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. J Mol Cell Cardiol 2006;41:934-948.
17. Gao Z, Xu H, Di Silvestre D, Halperin VL, Tunin R, Tian Y et al. Transcriptomic profiling of the canine tachycardia-induced heart failure model: global comparison to human and murine heart failure. J Mol Cell Cardiol 2006;40:76-86.
18. Ruiz P, Witt H. Microarray analysis to evaluate different animal models for human heart failure. J Mol Cell Cardiol 2006;40:13-15.
19. LaFramboise WA, Bombach KL, Dhir RJ, Muha N, Cullen RF, Pogozelski AR et al. Molecular dynamics of the compensatory response to myocardial infarct. J Mol Cell Cardiol 2005;38:103-117.
20. Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 2002;160:2035- 2043.
21. Grzeskowiak R, Witt H, Drungowski M, Thermann R, Hennig S, Perrot A et al. Expression profiling of human idiopathic dilated cardiomyopathy. Cardiovasc Res 2003;59:400-411.
22. Sanoudou D, Vafiadaki E, Arvanitis DA, Kranias E, Kontrogianni- Konstantopoulos A. Array lessons from the heart: focus on the genome and transcriptome of cardiomyopathies. Physiol Genom 2005;21:131-143.
23. Kodde IF, van der Stok J, Smolenski RT, de Jong JW. Metabolic and genetic regulation of cardiac energy substrate preference. Comp Biochem Physiol A Mol Integr Physiol 2007;146:26-39.
24. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-1480.
25. Schaub MC, Hefti MA, Zaugg M. Integration of calcium with the signaling network in cardiac myocytes. J Mol Cell Cardiol 2006;41:183-214.
26. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007;356:1140-1151.
27. Clerk A, Cullingford TE, Fuller SJ, Giraldo A, Markou T, Pikkarainen S et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 2007;212:311- 322.
28. Dorn GW 2nd. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 2007;49:962-970.
29. Dorn GW II, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005;115:527-537.
30. Markou T, Cullingford TE, Giraldo A, Weiss SC, Alsafi A, Fuller SJ et al. Glycogen synthase kinases 3alpha and 3beta in cardiac myocytes: Regulation and consequences of their inhibition. Cell Signal 2008;20:206-218.
31. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001;229:141-162.
32. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995;95:619-627.
33. Schaub MC, Hefti MA. The PGE2-Stat3 connection in cardiac hypertrophy. Cardiovasc Res 2007;73:3-5.
34. Strom CC, Aplin M, Ploug T, Christoffersen TE, Langfort J, Viese M et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 2005;272:2684-2695.
35. Kong SW, Bodyak N, Yue P, Liu Z, Brown J, Izumo S et al. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genom 2005;21:34-42.
36. da Silva R, Lucchinetti E, Pasch T, Schaub MC, Zaugg M. Ischemic but not pharmacological preconditioning elicits a gene expression profile similar to unprotected myocardium. Physiol Genom 2004;20:117-130.
37. Lucchinetti E, Hofer C, Bestmann L, Hersberger M, Feng J, Zhu M et al. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. Anesthesiology 2007;106:444-457.
38. McGregor E, Dunn MJ. Proteomics of the heart: unraveling disease. Circ Res 2006;98:309-321.
39. Lindsey ML, Goshorn DK, Comte-Walters S, Hendrick JW, Hapke E, Zile MR et al. A multidimensional proteomic approach to identify hypertrophy-associated proteins. Proteomics 2006;6:2225-2235.
40. Banfi C, Brioschi M, Wait R, Begum S, Gianazza E, Fratto P et al. Proteomic analysis of membrane microdomains derived from both failing and non-failing human hearts. Proteomics 2006;6:1976-1988.
41. van der Greef J, Stroobant P, van der Heijden R. The role of analytical sciences in medical systems biology. Curr Opin Chem Biol 2004;8:559-565.
42. Kell DB. Metabolomic biomarkers: search, discovery and validation. Expert Rev Mol Diagn 2007;7:329-333.
43. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 2007;104:1777-1782.
44. Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005;130:606-625.
45. Brown M, Dunn WB, Ellis DI, Goodacre R, Handl J, Knowles JD et al. A metabolome pipeline: from concept to data to knowledge. Metabolomics 2005;1:39-51.
46. Broadhurst D, Kell DB. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2006;2:171-196.
47. Kenny LC, Dunn WB, Ellis DI, Myers J, Baker PN; et al. GOPEC Consortium. Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning. Metabolomics 2005;1:227-234.
48. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C et al. Huntington disease patients and transgenic mice have similar procatabolic serum metabolite profiles. Brain 2006;129:877-886.
49. Dunn WB, Broadhurst DI, Deepak SM, Buch MH, McDowell G, Spasic I et al. Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics 2007;3:413-426.
50. Amuro Y, Nakaoka H, Shimomura S, Fujikura M, Yamamoto T, Tamura S et al. Serum pseudouridine as a biochemical marker in patients with hepatocellular carcinoma. Clin Chim Acta 1988;178:151-158.
51. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-262.
52. Swynghedauw B, Baillard C. Biology of hypertensive cardiopathy. Curr Opin Cardiol 2000;15:247-253.
53. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005;112:3868-3875.
54. Lucchinetti E, da Silva R, Pasch T, Schaub MC, Zaugg M. Anaesthetic preconditioning but not postconditioning prevents early activation of the deleterious cardiac remodelling programme: evidence of opposing genomic responses in cardioprotection by pre- and postconditioning. Br J Anaesth 2005;95:140-152.
55. Zaugg M, Lucchinetti E, Spahn DR, Pasch T, Schaub MC. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. Anesthesiology 2002;97:4-14.
56. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113-1151.
57. Zaugg M, Schaub MC. Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning. J Muscle Res Cell Motil 2003;24:219-249.
58. Sergeev P, da Silva R, Lucchinetti E, Zaugg K, Pasch T, Schaub MC et al. Trigger-dependent gene expression profiles in cardiac preconditioning: evidence for distinct genetic programs in ischemic and anesthetic preconditioning. Anesthesiology 2004;100:474-488.
59. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC, Zaugg M. Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology 2005;103:987-995.
60. Feng J, Fischer G, Lucchinetti E, Zhu M, Bestmann L, Jegger D et al. Infarct-remodeled myocardium is receptive to protection by isoflurane postconditioning: role of protein kinase B/Akt signaling. Anesthesiology 2006;104:1004-1014.
61. Zhu M, Feng J, Lucchinetti E, Fischer G, Xu L, Pedrazzini T et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res 2006;72:152-162.
62. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006;70:240-253.
63. Schaub MC, Lucchinetti E, Zaugg M. Genome reprogramming by triggering cardioprotective mechanisms. Bas Appl Myol 2007;17:151-160.
64. Mayr M, Zhang J, Greene AS, Gutterman D, Perloff J, Ping P. Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights. Mol Cell Proteom 2006;5:1853-1864.
65. Agnetti G, Kane LA, Guarnieri C, Caldarera CM, Van Eyk JE. Proteomic technologies in the study of kinases: novel tools for the investigation of PKC in the heart. Pharmacol Res 2007;55:511-522.
66. Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004;5:101-113.
67. Gerstein MB, Bruce C, Rozowsky JS, Zheng D, Du J, Korbel JO et al. What is a gene, post-ENCODE? History and updated definition. Genome Res 2007;17:669-681.
68. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007;316:1488-1491.
69. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007;316:1491-1493.
70. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007;39:857-864.
71. Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006;38:617-619.
72. Hakonarson H, Grant SF, Bradfield JP, Marchand L, Kim CE, Glessner JT et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007;448:591-594.
73. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D et al. A genomewide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-885.
74. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007;316:889-894.